PanGen Biotech Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	13,417	14,673	7,315	6,501	7,936
Other Revenue	-0	-0	-0	-	-
Revenue	13,417	14,673	7,315	6,501	7,936
Revenue Growth (YoY)	-8.56%	100.58%	12.53%	-18.08%	28.18%
Cost of Revenue	8,919	9,534	6,343	5,858	7,420
Gross Profit	4,498	5,139	971.8	642.47	515.69
Selling, General & Admin	1,653	1,768	1,536	1,272	969.85
Research & Development	1,382	2,012	3,332	3,850	2,734
Amortization of Goodwill & Intangibles	124.89	124.06	111.88	46.82	40.05
Other Operating Expenses	29.78	26.32	26.64	25.92	28
Operating Expenses	2,991	4,118	5,197	5,233	3,804
Operating Income	1,506	1,020	-4,225	-4,591	-3,288
Interest Expense	-145.87	-322.1	-220.68	-128.77	-293.25
Interest & Investment Income	424.43	184.78	41.75	246.57	179.7
Currency Exchange Gain (Loss)	-8.17	172.79	12.47	7.34	92.88
Other Non Operating Income (Expenses)	273.52	-91.83	-64.6	37.97	59.88
EBT Excluding Unusual Items	2,050	963.8	-4,457	-4,428	-3,249
Gain (Loss) on Sale of Assets	17.01	13.94	15.15	-0.24	-0.67
Other Unusual Items	-	25.85	-	-7.39	-
Pretax Income	2,067	1,004	-4,441	-4,435	-3,250
Income Tax Expense	16.53	59.9	47.43	58.69	60.5
Net Income	2,051	943.69	-4,489	-4,494	-3,310
Net Income to Common	2,051	943.69	-4,489	-4,494	-3,310
Net Income Growth	117.30%	-	-	-	-
Shares Outstanding (Basic)	13	12	11	11	10
Shares Outstanding (Diluted)	14	12	11	11	10
Shares Change (YoY)	22.05%	7.78%	0.03%	4.47%	6.02%
EPS (Basic)	154.00	82.00	-420.40	-421.00	-324.00
EPS (Diluted)	146.00	82.00	-420.40	-421.00	-324.00
EPS Growth	78.05%	-	-	-	-
Free Cash Flow	-373	2,627	-3,873	-4,231	-4,749
Free Cash Flow Per Share	-26.56	228.26	-362.70	-396.34	-464.83
Gross Margin	33.52%	35.02%	13.29%	9.88%	6.50%
Operating Margin	11.23%	6.95%	-57.76%	-70.62%	-41.44%
Profit Margin	15.28%	6.43%	-61.36%	-69.13%	-41.72%
Free Cash Flow Margin	-2.78%	17.90%	-52.94%	-65.08%	-59.85%
EBITDA	2,972	2,489	-2,629	-2,987	-1,756
EBITDA Margin	22.15%	16.96%	-35.94%	-45.96%	-22.13%
D&A For EBITDA	1,465	1,468	1,597	1,603	1,532
EBIT	1,506	1,020	-4,225	-4,591	-3,288
EBIT Margin	11.23%	6.95%	-57.76%	-70.62%	-41.44%
Effective Tax Rate	0.80%	5.97%	-	-	-

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.